CASP9 and B-cell non-Hodgkin lymphoma: The ivermectin–gemcitabine combination significantly increased the expression levels of B-cell lymphoma-associated X, caspase 3, and caspase 9 and decreased the levels of B-cell lymphoma-extra-large and B-cell lymphoma-2 compared to gemcitabine alone (Figures 3C,D).